{"id":"NCT00511342","sponsor":"Organon and Co","briefTitle":"Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)","officialTitle":"An Open-Label, Randomized, Single Center Trial in Healthy Young Women, to Evaluate the Effects of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg NOMAC and 1.5 mg E2 on Bone Mineral Density (BMD) Compared to a Monophasic COC Containing 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2007-08-03","resultsPosted":"2011-08-29","lastUpdate":"2022-02-09"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"NOMAC-E2","otherNames":["SCH 900121"]},{"type":"DRUG","name":"LNG-EE","otherNames":["SCH 900121"]}],"arms":[{"label":"NOMAC-E2","type":"EXPERIMENTAL"},{"label":"LNG-EE","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the effects of the NOMAC-E2 combined oral contraceptive (COC) on bone mineral density (BMD).","primaryOutcome":{"measure":"Mean Change From Baseline in Z-scores of the Lumbar Spine (L2-L4) and Femoral Neck","timeFrame":"Baseline and after cycle 26 (2 years)","effectByArm":[{"arm":"NOMAC-E2","deltaMin":0.019,"sd":0.242},{"arm":"LNG-EE","deltaMin":0.121,"sd":0.269}],"pValues":[{"comp":"OG000 vs OG001","p":"0.19"},{"comp":"OG000 vs OG001","p":"0.57"}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22762147"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Nasopharyngitis","Influenza","Mood altered","Acne","Headache"]}}